Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The basic biology of HER2.

I Rubin1, Y Yarden

  • 1Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Oncogene·2025
Same author

Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Oncogene·2024
Same author

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Cell death & disease·2022
Same author

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings.

CPT: pharmacometrics & systems pharmacology·2016
Same author

The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.

Oncogene·2015
Same author

An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.

Oncogene·2015
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Human epidermal growth factor receptor 2 (HER2) overexpression drives malignant growth in breast cancer by forming strong signaling heterodimers. Targeting HER2 with therapies like trastuzumab reduces HER2 availability, inhibiting cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Human epidermal growth factor receptors (HER/erbB) are key regulators of cell growth and differentiation.
  • HER2 forms potent heterodimers, amplifying growth signals when overexpressed.

Purpose of the Study:

  • To elucidate the role of HER2 in breast cancer and its potential as a therapeutic target.

Main Methods:

  • Analysis of HER receptor dimerization and signaling pathways.
  • Investigating the impact of HER2 overexpression on cell growth.
  • Evaluating the efficacy of anti-HER2 monoclonal antibody (trastuzumab).

Main Results:

  • HER2 is a preferred dimerization partner, forming strong signaling heterodimers.

Related Experiment Videos

  • HER2 overexpression leads to enhanced growth factor responsiveness and malignancy.
  • HER2 overexpression correlates with poor prognosis in breast tumors.

    • Conclusions:

    • HER2 overexpression is a critical driver of breast cancer progression.
    • Targeting HER2 with monoclonal antibodies like trastuzumab offers a promising therapeutic strategy by reducing HER2 availability and oncogenicity.